https://www.selleckchem.com/pr....oducts/gsk2656157.ht
5%) had a CR or PR. Two of the 5 patients with a long-term survival had immune-related adverse events grade 3 or 4 (IrAEs-3/4). None of the patients in the short-term survival group had IrAEs-3/4. The patients, who presented with IrAEs-3/4, which included colitis and adrenal insufficiency, continued to have a response off treatment. The median overall survival (OS) was 11.8 months (95% CI 7.8-15.4 months), with a 12-month OS of 46.6% (95% CI 33.4-58.8%) and a 3-year OS of 12.5% (95% CI 5.0-23.7%). We found a possible association betw
Like
Comment
Share
